| Drug Name |
Rasagiline mesylate |
| Drug ID |
BADD_D01916 |
| Description |
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. |
| Indications and Usage |
For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa. |
| Marketing Status |
Prescription |
| ATC Code |
N04BD02 |
| DrugBank ID |
DB01367
|
| KEGG ID |
D02562
|
| MeSH ID |
C031967
|
| PubChem ID |
3052775
|
| TTD Drug ID |
D06OMW
|
| NDC Product Code |
68546-229; 66039-878; 55111-900; 0378-1270; 57741-1900; 65015-775; 57741-2000; 43451-004; 68546-142; 23155-747; 0378-1271; 23155-746; 82245-0114; 65035-133 |
| Synonyms |
rasagiline | N-2-propynyl-1-indanamine | AGN 1135 | AGN-1135 | TVP 1022 | TVP1022 | TVP-1022 | N-propargyl-1-aminoindan mesylate | rasagiline hydrochloride | TVP 101 | TVP-101 | 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride | Azilect |
